Celldex Therapeutics Inc. (CLDX)

CLDX stock forecast: buy or sell

CLDX stock outlook

  • Celldex Therapeutics stock collapsed -6.93% to close at $11.55 on the stock market yesterday.
  • The stock is configuring an uptrend pattern since mid-March, when it bottomed at $1.50. This rally marked a 670% gain
  • Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics.
No ad for you

Important note:
The opinions given in this post are personal and should not be followed as recommendations for you to buy or sell stocks. The author of this text does not know the specific situations of the reader, his or her own financial statements or what is in his or her best interest at any given time. All users should speak with their financial advisor before buying or selling any securities Viewpoints are expressed for learning motives only

CLDX stock chart overview

Should I buy Celldex Therapeutics stock?

All successful traders recommend adhering to a trading strategy and not make decisions based on subjective opinions, rumors or feelings. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best

Is CLDX stock a buy?

Currently, Celldex Therapeutics stock doesn't match any of these trading strategies, so our recommendation is not to buy now. This doesn't mean CLDX will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems

No ad for you

Should I sell Celldex Therapeutics stock?

"To sell or not to sell", if you are holding Celldex Therapeutics shares?. Like when we have to buy shares, choosing when is appropiate to sell is not a capricious decision, and we must adhere our own trading strategy. When selling, as well as buying, detailed setups are very simple to use but are only applicable for selling stocks in your porfolio, not for shorting Celldex Therapeutics stock

As a golden rule, you should not keep a trade that shows a greater losses than those expected at the time of purchase. The timing to sell shares should always be ruled by the stop-loss (automatic or manual)

Is it time to sell Celldex Therapeutics stock?

Currently, Celldex Therapeutics stock doesn't match any of our preferred sell setups, so if you hold Celldex Therapeutics shares and your operation is in profit probably is not time to sell now

No ad for you

Analysts' recommendations to buy or sell Celldex Therapeutics stock

Brokerage firms and financial institutions post stock ratings based on their views of the market and the fundamental and technical situation of the analyzed stock. Unfortunately, the accuracy of these predictions is not very high, and certainly not a direct buy or sell signal

In the last 30 days, 2 ratings were published for Celldex Therapeutics. General sentiment is bullish, with 2 out of 2 publishing optimistic forecasts

No ad for you

Celldex Therapeutics ratings

Brokerage firmRating
Jun 12th, 2020
Cantor Fitzgerald Buy
Jul 1st, 2020
Cantor Fitzgerald Buy

Technical analysis

Celldex Therapeutics stock started an uptrend in mid-March, and gained an amazing 670%. The chart shows higher tops and bottoms, and along the way gave very few buy points for those who wanted to invest. Latest pullback was in mid-May, when price bounced at $2.20. Currently, it trades in a consolidation between its last top ($13.91) and its last bottom ($2.20)

SMAs overview

Moving averages are simple indicators for investors to detect momentum. A moving average is calculated as the simple mean of the previous N periods (usually sessions). Moving averages are usually calculated on different periods depending on the trading timeframe 21, 50, 100 and 200 days are the most usual moving averages. You can found more about Moving Averages from sources like Wikipedia and Investopedia

Supports and resistances

Market investors use support and resistance levels as a way to find price points in the stock price action that may act as glass ceiling, containing the price of an asset to move up or down. Supports are levels where the price may find support as it falls. This means that the price is more likely to "rebound" this level rather than break through it. However, if the price breaks down the support, it will probably continue falling until approaching another support level. On the other side, resistances are where the price may find opposition as it rises. In the same manner, the price is more liable to "rebound" at this level, and if it finally ruptures this level, the price will rally easily until it finds the next resistance

The current resistance levels are:

  • R1: $11.55 (0% above)
  • R2: $12.60 (9.09% above)
  • R3: $13.91 (20.43% above)
  • The current support levels are:

  • S1: $10.35 (-10.39% below)
  • S2: $9.75 (-15.58% below)
  • S3: $8.85 (-23.38% below)
  • Bollinger bands

    This is an indicator that was created in the 1980s by John Bollinger. In essence, the Bollinger Bands are lines that flow around a centralmoving average, varying the distance from the bottom to the top depending on market volatility. They are usually drawn by an interval of two standard deviations, above and below, from a moving average line. Bollinger himself recommends the moving average period to be 20

    Relative strength index

    The Relative Strength Index is an oscillator-type indicator that track price movements to spot when the share or financial asset is overbought or oversold. Oscillator indicators, such as relative strength, are intended to indicate values in the range of 0-100. The relative strength indicator is one of the best known and most widely used indicators, and it was invented by J. Welles Wilder in the late 1970s

    The RSI dropped below the overbought level of 70 on July 2 after just crossing to the overbough zone for a single day (weak signal). The RSI reading yesterday was 59.58. Since RSI lost the overbought zone, Celldex Therapeutics shares tanked a 13.68%

    No ad for you

    Earnings and financials

    In early May, CLDX hosted the quarterly shareholders call and released the first-quarter report. The market estimate is a a per-share earnings of %s of $-0.71, that is a 21.11% lower than previous reported quarter. CLDX reported 1st-quarter earnings of $-0.73 per share compared to Wall St estimate that was $-0.71.

    In contract, the EPS for the same quarter last year was $-1.40, so reported EPS is a increase of 47.86%. Sales merely changed on an annualized basis in the first-quarter, from $2.8M to $2.7M last quarter.

    CLDX is hosting the Q2 earnings call on early next August. Wall Street forecasts an Earnings per Share of $-0.81, compared to Q1 that was $-0.73. If you own or you are considering buying CLDX stock, you must be careful as the financial reporting day usually has a higher than usual volatility, and price can gap up or down with exceptionally low liquidity and not respecting your buy or stop-loss orders. You can obtain more details about the earnings conference call and the earnings reports on the Investor Relations section of its website: http://www.celldex.com.

    No ad for you